AU2017221268B2 - Methods comprising fixed intermittent dosing of cediranib - Google Patents

Methods comprising fixed intermittent dosing of cediranib Download PDF

Info

Publication number
AU2017221268B2
AU2017221268B2 AU2017221268A AU2017221268A AU2017221268B2 AU 2017221268 B2 AU2017221268 B2 AU 2017221268B2 AU 2017221268 A AU2017221268 A AU 2017221268A AU 2017221268 A AU2017221268 A AU 2017221268A AU 2017221268 B2 AU2017221268 B2 AU 2017221268B2
Authority
AU
Australia
Prior art keywords
cediranib
pdgfr
pdgf
days
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017221268A
Other languages
English (en)
Other versions
AU2017221268A1 (en
Inventor
Simon Barry
Tony Ho
Susan Percy Ivy
Jane Kendrew
Elise Kohn
Jung-Min Lee
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
United States Department of Health and Human Services
Original Assignee
AstraZeneca AB
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, Government of the United States of America filed Critical AstraZeneca AB
Publication of AU2017221268A1 publication Critical patent/AU2017221268A1/en
Application granted granted Critical
Publication of AU2017221268B2 publication Critical patent/AU2017221268B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017221268A 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib Active AU2017221268B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
US62/295,421 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (2)

Publication Number Publication Date
AU2017221268A1 AU2017221268A1 (en) 2018-08-30
AU2017221268B2 true AU2017221268B2 (en) 2024-02-15

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017221268A Active AU2017221268B2 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Country Status (16)

Country Link
US (1) US20210322415A1 (enExample)
EP (2) EP3417294B8 (enExample)
JP (2) JP6865762B2 (enExample)
KR (1) KR102830910B1 (enExample)
CN (1) CN109073650A (enExample)
AU (1) AU2017221268B2 (enExample)
CA (1) CA3014674C (enExample)
DK (1) DK3417294T3 (enExample)
ES (2) ES3074047T3 (enExample)
HU (1) HUE058114T2 (enExample)
MA (1) MA44251A (enExample)
MX (2) MX2018009867A (enExample)
PL (1) PL3417294T3 (enExample)
RU (1) RU2740849C2 (enExample)
TW (1) TWI827530B (enExample)
WO (1) WO2017142871A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
AR075239A1 (es) * 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2871589C (en) * 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOYCE F LIU ET AL: "A randomised phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer.", THE LANCET ONCOLOGY, vol. 15, no. 11, (2014-10-01), pages 1207 - 1214. *

Also Published As

Publication number Publication date
TWI827530B (zh) 2024-01-01
EP3417294B8 (en) 2022-05-04
JP7271594B2 (ja) 2023-05-11
EP3417294B1 (en) 2021-12-01
RU2018131377A3 (enExample) 2020-06-02
CN109073650A (zh) 2018-12-21
PL3417294T3 (pl) 2022-05-09
KR102830910B1 (ko) 2025-07-04
EP3417294A1 (en) 2018-12-26
HUE058114T2 (hu) 2022-07-28
JP2021105039A (ja) 2021-07-26
EP4071174B1 (en) 2026-05-27
EP3417294A4 (en) 2019-08-14
KR20180125456A (ko) 2018-11-23
US20210322415A1 (en) 2021-10-21
ES3074047T3 (en) 2026-07-16
MA44251A (fr) 2018-12-26
MX2023007826A (es) 2023-07-07
RU2018131377A (ru) 2020-03-17
CA3014674A1 (en) 2017-08-24
TW201906610A (zh) 2019-02-16
ES2906813T3 (es) 2022-04-20
JP6865762B2 (ja) 2021-04-28
WO2017142871A8 (en) 2018-06-14
EP4071174A1 (en) 2022-10-12
RU2740849C2 (ru) 2021-01-21
DK3417294T3 (da) 2022-02-21
WO2017142871A1 (en) 2017-08-24
MX2018009867A (es) 2019-05-27
CA3014674C (en) 2024-06-18
AU2017221268A1 (en) 2018-08-30
JP2019504860A (ja) 2019-02-21

Similar Documents

Publication Publication Date Title
JP7271594B2 (ja) セジラニブの一定間欠投与を含む方法
EP4504199A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
CN110730663B (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
CA2672933A1 (en) Method of treating cancer by a combined therapy of anticancer agents
TW201839399A (zh) 癌症治療
KR20230098279A (ko) Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
US20250041432A1 (en) Intermittent Dosing of Glucocorticoid Receptor Modulators for the Treatment of Ovarian and Other Cancers
TW201900176A (zh) 鉑類耐藥性癌症治療
HK40000757B (en) Methods comprising fixed intermittent dosing of cediranib
CN112915202A (zh) 喹啉衍生物与pd-1单抗的药物组合
JP2023523193A (ja) Ｃｓｆ－１ｒにより調節される疾患を治療するための投与レジメン
US20250161236A1 (en) Thymoquinone and black seed compositions for treating neuroendocrine cancer in combination with immunotherapy
TWI794984B (zh) 用於治療卵巢癌及其他癌症之糖皮質素受體調節劑的間歇投藥
UA128569C2 (uk) Дробне дозування модулятора глюкокортикоїдних рецепторів для лікування раку яєчника та інших видів раку
WO2021180027A1 (zh) 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
WO2019070497A1 (en) POLY THERAPY AGAINST CANCER
HK40105901A (en) Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合
CN118159538A (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
EP4401734A1 (en) Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
CN117956997A (zh) 糖皮质激素受体调节剂的间歇给予用于治疗卵巢癌和其他癌症
BR112016026197B1 (pt) Uso de medi4736 e tremelimumab

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)